StreetInsider.com News Articles

StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 08:01:10 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Enveric Biosciences responds to FDA final guidance on psychedelic drug development http://www.streetinsider.com/Corporate+News/Enveric+Biosciences+responds+to+FDA+final+guidance+on+psychedelic+drug+development/26822764.html <p>Enveric Biosciences (NASDAQ: ENVB) responded to the U.S. Food and Drug Administration's release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics, stating the guidance supports the design rationale behind its lead drug candidate, EB-003.</p><p>The FDA guidance identifies several clinical challenges associated with hallucinogenic compounds, including functional unblinding in trials, the difficulty of separating drug effects from accompanying psychotherapy, the need for prolonged patient observation by trained monitors, and questions around abuse potential and repeat dosing.</p><p>Enveric's EB-003 is designed to engage neuroplasticity-related receptor signaling associated with classic psychedelics while avoiding a hallucinogenic experience. The company said that if http://www.streetinsider.com/Corporate+News/Enveric+Biosciences+responds+to+FDA+final+guidance+on+psychedelic+drug+development/26822764.html Tue, 28 Jul 2026 08:01:10 -0400 ENVB Enveric Biosciences responds to FDA final guidance on psychedelic drug development http://www.streetinsider.com/FDA/Enveric+Biosciences+responds+to+FDA+final+guidance+on+psychedelic+drug+development/26822764.html <p>Enveric Biosciences (NASDAQ: ENVB) responded to the U.S. Food and Drug Administration's release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics, stating the guidance supports the design rationale behind its lead drug candidate, EB-003.</p><p>The FDA guidance identifies several clinical challenges associated with hallucinogenic compounds, including functional unblinding in trials, the difficulty of separating drug effects from accompanying psychotherapy, the need for prolonged patient observation by trained monitors, and questions around abuse potential and repeat dosing.</p><p>Enveric's EB-003 is designed to engage neuroplasticity-related receptor signaling associated with classic psychedelics while avoiding a hallucinogenic experience. The company said that if http://www.streetinsider.com/FDA/Enveric+Biosciences+responds+to+FDA+final+guidance+on+psychedelic+drug+development/26822764.html Tue, 28 Jul 2026 08:01:10 -0400 ENVB Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html <p> <i>FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54576694&newsitemid=20260728654467&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=6f1a0796da36246f4f529edaa23f13a8" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. </p><p> “The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Welcomes+Final+FDA+Guidance+for+Psychedelic+Drug+Development/26822588.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 ENVB O.05138206 O.20026344 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enveric.com&esheet=54561231&newsitemid=20260629700344&lan=en-US&anchor=Enveric+Biosciences&index=1&md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 Enveric Biosciences Announces Participation in 2026 BIO International Convention http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 Enveric Biosciences Announces Participation in 2026 BIO International Convention http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 Enveric Biosciences Announces Participation in 2026 BIO International Convention http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 Enveric Biosciences Announces Participation in 2026 BIO International Convention http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 Form 8-K Enveric Biosciences, For: Jun 09 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html si-local-file:///var/storage/secattach/20260609/26624795.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html Tue, 09 Jun 2026 17:17:00 -0400 ENVB O.05138206 Form 8-K Enveric Biosciences, For: Jun 09 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html si-local-file:///var/storage/secattach/20260609/26624795.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html Tue, 09 Jun 2026 17:17:00 -0400 ENVB O.05138206 Form 424B5 Enveric Biosciences, http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Enveric+Biosciences%2C+++++++++++++++++/26624777.html si-local-file:///var/storage/secattach/20260609/26624777.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Enveric+Biosciences%2C+++++++++++++++++/26624777.html Tue, 09 Jun 2026 17:15:00 -0400 ENVB O.05138206